Inventage Lab Secures Domestic Patent for Long-Acting Injectable Technology for Oral Obesity Drug

Proven Delivery Technology Encompassing GLP-1 Class Small Molecules and Peptides

Inventage Lab Co., Ltd., a drug delivery platform company, announced on January 28 that it has registered a domestic patent for its technology that formulates the next-generation obesity and diabetes treatment candidate, the small molecule compound "Orforglipron," as a long-acting injectable.

This patent marks the first case of securing rights for the implementation of Orforglipron as a long-acting injectable. The company explained, "We have completed an international application under the Patent Cooperation Treaty (PCT) and plan to proceed with entry procedures in major global markets such as the United States, Europe, and Japan based on this patent."

Inventage Lab has secured key patents for applying glucagon-like peptide-1 (GLP-1) class small molecule compounds and peptide drugs to its "IVL-DrugFluidic®" platform, enabling stable encapsulation in biodegradable polymers and the production of uniform micro-particles. Previously, through a patent registration for a semaglutide-based formulation jointly developed with Yuhan Corporation, the company succeeded in securing rights to specific pharmacokinetic control technology that manages initial release after administration while maintaining consistent blood concentrations over an extended period.

The recently patented Orforglipron is an oral small molecule GLP-1 drug under development by Eli Lilly, which has shown excellent weight loss effects in obese patients. By combining Inventage Lab's platform technology with this oral drug, a single injection can provide effects lasting one to three months. This is expected to improve patient adherence by eliminating the inconvenience of daily medication.

The core of this patent lies in its sophisticated control of initial drug release. It minimizes gastrointestinal side effects such as nausea, vomiting, and diarrhea, which can occur due to rapid increases in drug concentration after oral administration, while also enhancing bioavailability to maintain stable long-term therapeutic effects.

Juhui Kim, CEO of Inventage Lab, stated, "With our already secured core registered patents and this first patent registration for Orforglipron, Inventage Lab has proven its leading technology in developing long-acting injectable formulations for obesity treatments. Based on this technological strength, we will continue to enhance our capabilities in long-acting injectable formulations for various peptide and small molecule-based treatments for obesity and metabolic diseases."

This content was produced with the assistance of AI translation services.